1. Home
  2. NMI vs ACOG Comparison

NMI vs ACOG Comparison

Compare NMI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Income Fund Inc.

NMI

Nuveen Municipal Income Fund Inc.

HOLD

Current Price

$10.18

Market Cap

111.9M

Sector

Finance

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$4.99

Market Cap

129.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMI
ACOG
Founded
1988
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
111.9M
129.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NMI
ACOG
Price
$10.18
$4.99
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
28.4K
74.8K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
4.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.30
$3.75
52 Week High
$10.05
$11.54

Technical Indicators

Market Signals
Indicator
NMI
ACOG
Relative Strength Index (RSI) 57.55 49.64
Support Level $10.06 $4.75
Resistance Level $10.25 $5.99
Average True Range (ATR) 0.11 0.58
MACD 0.02 0.04
Stochastic Oscillator 79.07 63.36

Price Performance

Historical Comparison
NMI
ACOG

About NMI Nuveen Municipal Income Fund Inc.

Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: